Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.

Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM.

Invest New Drugs. 2018 Aug;36(4):523-535. doi: 10.1007/s10637-017-0543-z. Epub 2018 Feb 19.

PMID:
29460212
2.

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.

O'Boyle NM, Barrett I, Greene LM, Carr M, Fayne D, Twamley B, Knox AJS, Keely NO, Zisterer DM, Meegan MJ.

J Med Chem. 2018 Jan 25;61(2):514-534. doi: 10.1021/acs.jmedchem.6b01917. Epub 2017 May 1.

PMID:
28426931
3.

β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.

Malebari AM, Greene LM, Nathwani SM, Fayne D, O'Boyle NM, Wang S, Twamley B, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2017 Apr 21;130:261-285. doi: 10.1016/j.ejmech.2017.02.049. Epub 2017 Feb 24.

PMID:
28254699
4.

Severity of Nasal Inflammatory Disease Questionnaire for Canine Idiopathic Rhinitis Control: Instrument Development and Initial Validity Evidence.

Greene LM, Royal KD, Bradley JM, Lascelles BD, Johnson LR, Hawkins EC.

J Vet Intern Med. 2017 Jan;31(1):134-141. doi: 10.1111/jvim.14629. Epub 2016 Dec 25.

5.

Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

Greene LM, Butini S, Campiani G, Williams DC, Zisterer DM.

J Cancer. 2016 Dec 4;7(15):2367-2377. eCollection 2016. Review.

7.

The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.

Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM.

Int J Oncol. 2016 Jul;49(1):74-88. doi: 10.3892/ijo.2016.3518. Epub 2016 May 12.

8.

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.

Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM.

Invest New Drugs. 2016 Apr;34(2):159-67. doi: 10.1007/s10637-016-0331-1. Epub 2016 Feb 17.

PMID:
26885657
9.

Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.

Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ.

J Med Chem. 2016 Jan 14;59(1):90-113. doi: 10.1021/acs.jmedchem.5b01086. Epub 2015 Dec 17.

PMID:
26680364
10.

Combretastatins: more than just vascular targeting agents?

Greene LM, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2015 Nov;355(2):212-27. doi: 10.1124/jpet.115.226225. Epub 2015 Sep 9. Review.

PMID:
26354991
11.

Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.

Greene LM, Nolan DP, Regan-Komito D, Campiani G, Williams DC, Zisterer DM.

Int J Oncol. 2013 Sep;43(3):927-35. doi: 10.3892/ijo.2013.1989. Epub 2013 Jun 25.

PMID:
23799546
12.

Associations among exercise duration, lameness severity, and hip joint range of motion in Labrador Retrievers with hip dysplasia.

Greene LM, Marcellin-Little DJ, Lascelles BD.

J Am Vet Med Assoc. 2013 Jun 1;242(11):1528-33. doi: 10.2460/javma.242.11.1528.

PMID:
23683017
13.

Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.

Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Jun;29(6):2451-8. doi: 10.3892/or.2013.2379. Epub 2013 Apr 3.

PMID:
23564200
14.

Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.

O'Boyle NM, Greene LM, Keely NO, Wang S, Cotter TS, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2013 Apr;62:705-21. doi: 10.1016/j.ejmech.2013.01.016. Epub 2013 Jan 18.

PMID:
23454513
15.

Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.

Nathwani SM, Hughes L, Greene LM, Carr M, O'Boyle NM, McDonnell S, Meegan MJ, Zisterer DM.

Oncol Rep. 2013 Feb;29(2):585-94. doi: 10.3892/or.2012.2181. Epub 2012 Dec 10.

PMID:
23232969
16.

The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells.

Greene LM, O'Boyle NM, Nolan DP, Meegan MJ, Zisterer DM.

Biochem Pharmacol. 2012 Sep 1;84(5):612-24. doi: 10.1016/j.bcp.2012.06.005. Epub 2012 Jun 15.

PMID:
22705646
17.

Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.

O'Boyle NM, Carr M, Greene LM, Keely NO, Knox AJ, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2011 Sep;46(9):4595-607. doi: 10.1016/j.ejmech.2011.07.039. Epub 2011 Jul 28.

PMID:
21840628
18.

Effect of method and clinician on stallion sperm morphology evaluation.

Brito LF, Greene LM, Kelleman A, Knobbe M, Turner R.

Theriogenology. 2011 Sep 1;76(4):745-50. doi: 10.1016/j.theriogenology.2011.04.007. Epub 2011 May 25.

PMID:
21612814
19.

Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.

O'Boyle NM, Greene LM, Bergin O, Fichet JB, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

Bioorg Med Chem. 2011 Apr 1;19(7):2306-25. doi: 10.1016/j.bmc.2011.02.022. Epub 2011 Feb 17.

PMID:
21397510
20.

BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.

Greene LM, Carr M, Keeley NO, Lawler M, Meegan MJ, Zisterer DM.

Int J Mol Med. 2011 May;27(5):715-23. doi: 10.3892/ijmm.2011.633. Epub 2011 Mar 2.

PMID:
21369694
21.

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.

O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ.

J Med Chem. 2010 Dec 23;53(24):8569-84. doi: 10.1021/jm101115u. Epub 2010 Nov 16.

PMID:
21080725
22.

Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.

Carr M, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

Eur J Med Chem. 2010 Dec;45(12):5752-66. doi: 10.1016/j.ejmech.2010.09.033. Epub 2010 Sep 22.

PMID:
20933304
23.

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2010 Nov;335(2):302-13. doi: 10.1124/jpet.110.170415. Epub 2010 Aug 10.

PMID:
20699436
24.

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):180-94. doi: 10.3109/14756360903169659.

PMID:
20222762
25.

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M.

Cancer Res. 2009 Nov 1;69(21):8366-75. doi: 10.1158/0008-5472.CAN-09-0131. Epub 2009 Oct 13.

26.

Semen characteristics in a sub-fertile Arabian stallion with idiopathic teratospermia.

Brito LF, Kelleman A, Greene LM, Raz T, Barth AD.

Reprod Domest Anim. 2010 Apr;45(2):354-8. doi: 10.1111/j.1439-0531.2008.01252.x. Epub 2009 Jan 8.

PMID:
19144036
27.

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.

Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.

Biochem Pharmacol. 2009 Feb 1;77(3):310-21. doi: 10.1016/j.bcp.2008.10.008. Epub 2008 Oct 30.

PMID:
19014913
28.

BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.

Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM.

Mol Pharmacol. 2008 Feb;73(2):419-30. Epub 2007 Nov 8.

PMID:
17991869
29.
30.

Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.

Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM.

Mol Pharmacol. 2006 Jul;70(1):60-70. Epub 2006 Mar 29.

PMID:
16571652
31.

The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo.

Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC, Zisterer DM.

Oncol Rep. 2005 Nov;14(5):1357-63.

PMID:
16211309
33.

Fibulins: physiological and disease perspectives.

Argraves WS, Greene LM, Cooley MA, Gallagher WM.

EMBO Rep. 2003 Dec;4(12):1127-31. Review.

34.

Elevated expression and altered processing of fibulin-1 protein in human breast cancer.

Greene LM, Twal WO, Duffy MJ, McDermott EW, Hill AD, O'Higgins NJ, McCann AH, Dervan PA, Argraves WS, Gallagher WM.

Br J Cancer. 2003 Mar 24;88(6):871-8.

35.

More uses for a tax credit.

Greene LM.

Health Aff (Millwood). 2001 Sep-Oct;20(5):303. No abstract available.

PMID:
11558719
36.

Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues.

Gallagher WM, Greene LM, Ryan MP, Sierra V, Berger A, Laurent-Puig P, Conseiller E.

FEBS Lett. 2001 Jan 26;489(1):59-66.

37.

The role of radiology in pulmonary infectious disease.

Tenholder MF, Greene LM, Thomas AM.

Curr Opin Pulm Med. 1998 May;4(3):142-7. Review.

PMID:
9675516
38.

Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitis.

McClave SA, Greene LM, Snider HL, Makk LJ, Cheadle WG, Owens NA, Dukes LG, Goldsmith LJ.

JPEN J Parenter Enteral Nutr. 1997 Jan-Feb;21(1):14-20.

PMID:
9002079
39.

Central lines have moved out.

Greene LM, Gerlach CJ.

RN. 1994 May;57(5):26-30; quiz 31. No abstract available.

PMID:
8197384
40.

New peripherally inserted midline catheter: a better alternative for intravenous antibiotic therapy in patients with cystic fibrosis.

Harwood IR, Greene LM, Kozakowski-Koch JA, Rasor JS.

Pediatr Pulmonol. 1992 Apr;12(4):233-9.

PMID:
1614749
41.

Nutritional support in patients with inflammatory bowel disease.

Lowen CC, Greene LM, McClave SA.

Postgrad Med. 1992 Apr;91(5):407-14.

PMID:
1561174
42.

Use of residual volume as a marker for enteral feeding intolerance: prospective blinded comparison with physical examination and radiographic findings.

McClave SA, Snider HL, Lowen CC, McLaughlin AJ, Greene LM, McCombs RJ, Rodgers L, Wright RA, Roy TM, Schumer MP, et al.

JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):99-105.

PMID:
1556825

Supplemental Content

Loading ...
Support Center